Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AQST Aquestive Therapeutics	$3.68 -0.5%	$3.02	$2.12 ▼ $5.80	$365.53M	1.97	1.49 million shs	871,879 shs
BGM BGM Group	$9.93 -0.7%	$12.47	$5.26 ▼ $17.17	$965.40M	1.29	34,118 shs	23,391 shs
ELVN Enliven Therapeutics	$19.93 +1.7%	$19.60	$13.30 ▼ $30.03	$977.97M	0.83	297,941 shs	300,761 shs
MLYS Mineralys Therapeutics	$13.95 +3.1%	$14.94	$8.24 ▼ $18.38	$909.26M	-0.3	550,245 shs	767,190 shs

A Beginner's Guide to Investing in Cannabis

Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AQST Aquestive Therapeutics	-0.54%	+11.78%	+3.93%	+56.12%	+49.19%
BGM BGM Group	-2.06%	-5.57%	-23.55%	-4.76%	+999,999,900.00%
ELVN Enliven Therapeutics	-5.25%	-2.34%	-5.54%	+23.83%	-12.62%
MLYS Mineralys Therapeutics	-6.85%	0.00%	-16.07%	+14.95%	+8.85%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
AQST Aquestive Therapeutics	1.2488 of 5 stars	3.5	1.0	0.0	0.0	1.9	0.0	0.0
BGM BGM Group	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
ELVN Enliven Therapeutics	2.6826 of 5 stars	3.5	0.0	0.0	0.0	3.7	4.2	0.0
MLYS Mineralys Therapeutics	2.1521 of 5 stars	3.4	1.0	0.0	0.0	1.4	4.2	0.0

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AQST Aquestive Therapeutics	3.00	Buy	$10.14	175.62% Upside
BGM BGM Group	0.00	N/A	N/A	N/A
ELVN Enliven Therapeutics	3.00	Buy	$41.20	106.72% Upside
MLYS Mineralys Therapeutics	2.75	Moderate Buy	$32.25	131.18% Upside

Current Analyst Ratings Breakdown

Latest AQST, BGM, MLYS, and ELVN Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
7/2/2025	ELVN Enliven Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$40.00 ➝ $48.00
6/17/2025	AQST Aquestive Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00
6/17/2025	MLYS Mineralys Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$42.00
6/16/2025	ELVN Enliven Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Outperform ➝ Outperform	$40.00 ➝ $52.00
6/16/2025	ELVN Enliven Therapeutics	The Goldman Sachs Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Buy	$37.00
6/10/2025	MLYS Mineralys Therapeutics	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Hold	$15.00
6/2/2025	AQST Aquestive Therapeutics	Oppenheimer Subscribe to MarketBeat All Access for the recommendation accuracy rating	Initiated Coverage	Outperform	$7.00
5/16/2025	ELVN Enliven Therapeutics	Jones Trading Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$36.00 ➝ $27.00
5/15/2025	AQST Aquestive Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$10.00 ➝ $10.00
5/15/2025	ELVN Enliven Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$39.00 ➝ $40.00
5/14/2025	MLYS Mineralys Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the recommendation accuracy rating	Set Price Target	Buy ➝ Buy	$48.00

(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AQST Aquestive Therapeutics	$57.56M	6.35	N/A	N/A	($0.66) per share	-5.58
BGM BGM Group	$25.10M	38.46	N/A	N/A	$7.34 per share	1.35
ELVN Enliven Therapeutics	N/A	N/A	N/A	N/A	$6.34 per share	N/A
MLYS Mineralys Therapeutics	N/A	N/A	N/A	N/A	$3.84 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AQST Aquestive Therapeutics	-$44.14M	-$0.59	N/A	N/A	N/A	-100.02%	N/A	-50.31%	8/5/2025 (Estimated)
BGM BGM Group	-$1.44M	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
ELVN Enliven Therapeutics	-$89.02M	-$1.92	N/A	N/A	N/A	N/A	-31.84%	-30.09%	8/12/2025 (Estimated)
MLYS Mineralys Therapeutics	-$177.81M	-$3.73	N/A	N/A	N/A	N/A	-71.15%	-65.71%	8/12/2025 (Estimated)

Latest AQST, BGM, MLYS, and ELVN Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/5/2025	Q2 2025	AQST Aquestive Therapeutics	-$0.18	N/A	N/A	N/A	$11.32 million	N/A
5/14/2025	Q1 2025	ELVN Enliven Therapeutics	-$0.51	-$0.57	-$0.06	-$0.57	N/A	N/A
5/12/2025	Q1 2025	AQST Aquestive Therapeutics	-$0.17	-$0.24	-$0.07	-$0.24	$12.23 million	$8.72 million
5/12/2025	Q1 2025	MLYS Mineralys Therapeutics	-$1.02	-$0.79	+$0.23	-$0.79	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
AQST Aquestive Therapeutics	N/A	N/A	N/A	N/A	N/A
BGM BGM Group	N/A	N/A	N/A	N/A	N/A
ELVN Enliven Therapeutics	N/A	N/A	N/A	N/A	N/A
MLYS Mineralys Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AQST Aquestive Therapeutics	N/A	4.87	4.48
BGM BGM Group	N/A	N/A	N/A
ELVN Enliven Therapeutics	N/A	21.07	21.06
MLYS Mineralys Therapeutics	N/A	26.48	26.48

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AQST Aquestive Therapeutics	32.45%
BGM BGM Group	N/A
ELVN Enliven Therapeutics	95.08%
MLYS Mineralys Therapeutics	84.46%

Insider Ownership

Company	Insider Ownership
AQST Aquestive Therapeutics	7.85%
BGM BGM Group	58.66%
ELVN Enliven Therapeutics	25.90%
MLYS Mineralys Therapeutics	33.24%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AQST Aquestive Therapeutics	160	99.33 million	91.53 million	Optionable
BGM BGM Group	298	97.22 million	40.19 million	N/A
ELVN Enliven Therapeutics	50	49.07 million	36.36 million	Optionable
MLYS Mineralys Therapeutics	28	65.18 million	43.51 million	Optionable

AQST, BGM, MLYS, and ELVN Headlines

Recent News About These Companies

Mineralys Therapeutics (NASDAQ:MLYS) Shares Down 6.2% - Time to Sell?

July 7 at 12:50 PM | marketbeat.com

Mineralys Therapeutics Announces Positive Phase 3 Launch-HTN Trial Results for Lorundrostat in Uncontrolled Hypertension - Nasdaq

July 2, 2025 | nasdaq.com

Here's Why We're Watching Mineralys Therapeutics' (NASDAQ:MLYS) Cash Burn Situation

July 2, 2025 | finance.yahoo.com

Mineralys Therapeutics Reports Positive Topline Data from Phase 2 Explore-CKD Trial of Lorundrostat

July 1, 2025 | msn.com

Mineralys Therapeutics Announces Journal of the American Medical Association (JAMA) Publication of Pivotal Phase 3 Launch-HTN Trial for Lorundrostat

June 30, 2025 | globenewswire.com

MLYS - Mineralys Therapeutics Inc Key Metrics - Morningstar

June 26, 2025 | morningstar.comM

Research Analysts Issue Forecasts for MLYS Q2 Earnings

June 19, 2025 | marketbeat.com

Mineralys enhances lorundrostat data package ahead of planned NDA

June 18, 2025 | thepharmaletter.comT

Promising Trial Results for Lorundrostat Boost Mineralys Therapeutics’ Investment Appeal

June 18, 2025 | tipranks.com

Mineralys Therapeutics: Investigational Drug Shows Benefit In Hypertensive Patients With Chronic Kidney Disease, Stock Jumps

June 17, 2025 | benzinga.com

Mineralys Therapeutics (NASDAQ:MLYS) Stock Price Up 5.6% - Should You Buy?

June 17, 2025 | marketbeat.com

Mineralys Therapeutics' (MLYS) Buy Rating Reaffirmed at HC Wainwright

June 17, 2025 | marketbeat.com

Positive Phase II Results for Mineralys Therapeutics’ Lorundrostat Support Buy Rating

June 17, 2025 | tipranks.com

Mineralys' hypertension drug continues winning streak, lowering blood pressure in phase 2

June 17, 2025 | fiercebiotech.comF

Mineralys Therapeutics stock jumps after positive kidney disease trial data

June 17, 2025 | investing.com

Mineralys Therapeutics Shares Climb on Strong Results from Kidney Disease Trial

June 17, 2025 | msn.com

Mineralys Therapeutics Announces Positive Topline Results from Phase 2 Explore-CKD Trial of Lorundrostat for the Treatment of Hypertension in Subjects with CKD and Albuminuria

June 17, 2025 | globenewswire.com

Mineralys Therapeutics (NASDAQ:MLYS) Shares Down 4.5% - Should You Sell?

June 16, 2025 | marketbeat.com

Mineralys Therapeutics (NASDAQ:MLYS) Cut to Sell at Wall Street Zen

June 14, 2025 | marketbeat.com

Jefferies initiates Mineralys Therapeutics stock with hold rating

June 11, 2025 | uk.investing.com

Jefferies Initiates Coverage of Mineralys Therapeutics (MLYS) with Hold Recommendation

June 11, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

AQST, BGM, MLYS, and ELVN Company Descriptions

Aquestive Therapeutics NASDAQ:AQST

$3.68 -0.02 (-0.54%)

Closing price 04:00 PM Eastern

Extended Trading

$3.61 -0.07 (-1.90%)

As of 06:28 PM Eastern

Aquestive Therapeutics, Inc. operates as a pharmaceutical company in the United States and internationally. The company markets Sympazan, an oral soluble film formulation of clobazam for the treatment of lennox-gastaut syndrome; Suboxone, a sublingual film formulation of buprenorphine and naloxone for the treatment of opioid dependence; Zuplenz, an oral soluble film formulation of ondansetron for the treatment of nausea and vomiting associated with chemotherapy and post-operative recovery; and Azstarys, a once-daily product for the treatment of attention deficit hyperactivity disorder. Its proprietary product candidates comprise Libervant, a buccal soluble film formulation of diazepam for the treatment of seizures; KYNMOBI, a sublingual film formulation of apomorphine for the treatment of episodic off-periods in Parkinson's disease; and Exservan, an oral soluble film formulation of riluzole for the treatment of amyotrophic lateral sclerosis. The company's proprietary pipeline of complex molecule product includes AQST-108, a sublingual film formulation delivering systemic epinephrine for the treatment of conditions other than anaphylaxis; and Anaphylm, an epinephrine sublingual film for the emergency treatment of allergic reactions, including anaphylaxis. In addition, it develops Adrenaverse, an epinephrine prodrug platform. The company was incorporated in 2004 and is headquartered in Warren, New Jersey.

BGM Group NASDAQ:BGM

$9.93 -0.07 (-0.70%)

Closing price 04:00 PM Eastern

Extended Trading

$10.01 +0.08 (+0.76%)

As of 05:10 PM Eastern

Qilian International Holding Group Limited manufactures and distributes active pharmaceutical ingredients (APIs), traditional Chinese medicine derivatives (TCMD), and other by-products in China. The company provides licorice products, including Gan Di Xin, an antitussive and expectorant medicine; Qilian Shan Licorice Extract, an ingredient for pharmaceutical companies to manufacture traditional licorice tablets; and Qilian Shan licorice liquid extract, a primary ingredient for medical preparation companies to produce compound licorice oral solutions. It offers Qilian Shan oxytetracycline tablets to prevent and treat a range of diseases in chickens, turkeys, cattle, swine, and human; and Qilian Shan oxytetracycline APIs for pharmaceutical companies to manufacture medications. In addition, the company offers TCMD products, such as Ahan antibacterial paste to treat refractory chronic skin diseases; heparin products, including heparin sodium preparations for pharmaceutical companies to produce medications for cardiovascular diseases, cerebrovascular diseases, and hemodialysis; and Zhu Xiaochang sausage casings, which are natural food products for culinary application. Further, it provides Xiongguan organic fertilizers to improve crop yield and soil's chemical properties and reduce soil compaction; and Xiongguan organic-inorganic compound fertilizers to increased plant growth. Qilian International Holding Group Limited was incorporated in 2019 and is based in Jiuquan, the People's Republic of China.

Enliven Therapeutics NASDAQ:ELVN

$19.93 +0.34 (+1.74%)

As of 04:00 PM Eastern

Enliven Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of small molecule inhibitors to help patients with cancer. The company's lead product candidates comprise ELVN-001, which is being evaluated in a Phase 1 clinical trial in adults with chronic myeloid leukemia; and ELVN-002, a Phase 1 clinical trial in adults with solid tumors with HER2 alterations. The company is headquartered in Boulder, Colorado.

Mineralys Therapeutics NASDAQ:MLYS

$13.95 +0.42 (+3.10%)

Closing price 04:00 PM Eastern

Extended Trading

$13.94 0.00 (-0.04%)

As of 04:37 PM Eastern

Mineralys Therapeutics, Inc., a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc. and changed its name to Mineralys Therapeutics, Inc. in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time